Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Blood. 2019 Aug 22;134(8):713-716. doi: 10.1182/blood.2019000904. Epub 2019 Jul 16.

¹ Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
² Section for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
³ Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg and Hopp Children's Cancer Center at Nationales Centrum für Tumorerkrankungen Heidelberg, Heidelberg, Germany.
⁴ Institute of Human Genetics, Medical School Hannover, Hannover, Germany.
⁵ Institute of Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany; and.
⁶ Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, University Hospital, Ludwig Maximilians University Munich, Munich, Germany.

No abstract available

Publication types